Skip to main
ENGN
ENGN logo

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 13%
Buy 75%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

enGene Holdings Inc. is in a strong position for future growth due to the receipt of RMAT designation for its lead product, detalimogene, which is expected to enhance its market share, particularly in community practice settings. The company has identified additional opportunity for expansion through its LEGEND study cohorts, which could broaden the addressable market by including earlier disease stages and active surveillance. Although research and development expenses have risen significantly to $22.6 million in 3Q25, this increase reflects the commitment to advancing its clinical trials and manufacturing capabilities, essential for long-term product development success.

Bears say

A negative outlook on enGene Holdings's stock is primarily driven by the risk of failing to achieve regulatory approval or facing delays in approval timelines, which could significantly impact the company’s share price. Additionally, the operational challenges associated with the TAR-200 product, including a 24% serious adverse event rate and approximately 7% discontinuation rate, may hinder its market adoption and overall commercial success. Finally, any dissatisfaction with TAR-200's operational burden could further accelerate the competitive uptake of detalimogene, posing additional risks to enGene’s market position.

ENGN has been analyzed by 8 analysts, with a consensus rating of Buy. 13% of analysts recommend a Strong Buy, 75% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 8 analysts, ENGN has a Buy consensus rating as of Nov 19, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.